As of April 2026, compounded GLP-1 medications remain available through certain pharmacy pathways, though the landscape has contracted compared to 2023 and 2024 following regulatory changes
Prolonged disequilibrium of NAD + metabolism disturbs the physiological functions, resulting in diseases including metabolic diseases, cancer, aging and neurodegeneration disorder
Although it does not explicitly appear on the prohibited substances list in 2026, it could be classified under the category of peptide growth factors (section S2 of the prohibited list)
Calorie restriction increases cigarette use in adult smokers
GHK-Cu (Copper Peptide): Known for its exceptional skin-regenerating properties, GHK-Cu stimulates collagen and elastin synthesis
GLP-1 and Adhesions, Fibrosis, and Scar Tissue Another major focus of this episode is how GLP-1 medications may influence fibrosis and scar tissue signaling